Accounts receivable, net of allowance for credit losses |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts receivable, net of allowance for credit losses | Accounts receivable, net of allowance for credit losses The following table provides details of the Company’s allowance for credit losses on accounts receivable:
Accounts receivable were $1,424,035 and $1,262,647, and allowances for credit losses were $21,220 and $22,097, resulting in net accounts receivable balances of $1,402,815 and $1,240,550 as of June 30, 2026 and December 31, 2025, respectively. 4. Accounts receivable, net of allowance for credit losses (Continued) In addition, deferred billings were $297,009 and $232,647 and allowances for credit losses on deferred billings were $13,438 and $10,659, resulting in net deferred billings balances of $283,571 and $221,988 as of June 30, 2026 and December 31, 2025, respectively. During the three months ended June 30, 2026 and 2025, the Company recorded charges of $1,003 and $1,989, respectively, and for the six months ended June 30, 2026 and 2025, a charge of $2,779 and $541, respectively, to the income statement on account of credit losses on deferred billings. Deferred billings, net of related allowances for credit losses, are included under “Other assets” in the Company’s consolidated balance sheets as of June 30, 2026 and December 31, 2025. The Company has a revolving accounts receivable-based facility of $100,000 as of June 30, 2026 and December 31, 2025 that permits it to sell accounts receivable to banks on a non-recourse basis in the ordinary course of business. The aggregate maximum capacity utilized by the Company at any time during the six months ended June 30, 2026 and year ended December 31, 2025 was $79,461 and $59,952, respectively. The principal amount outstanding against this facility as of June 30, 2026 and December 31, 2025 was $77,081 and $55,140, respectively. The cost of factoring such accounts receivable during the three and six months ended June 30, 2026 and 2025 was $726 and $403, respectively, and $1,407 and $1,081, respectively. Gains or losses on the sales are recorded at the time of transfer of the accounts receivable and are included under "interest income (expense), net" in the Company’s consolidated statements of income. The Company also has arrangements with financial institutions that manage the accounts payable program for certain of the Company's large clients. The Company sells certain accounts receivable pertaining to such clients to these financial institutions on a non-recourse basis. There is no cap on the value of accounts receivable that can be sold under these arrangements. The Company used these arrangements to sell accounts receivable amounting to $147,315 during the six months ended June 30, 2026 and $327,207 during the year ended December 31, 2025, which also represent the maximum capacity utilized under these arrangements in each such period. The cost of factoring such accounts receivable during the three and six months ended June 30, 2026 and 2025 was $1,143 and $1,403, respectively, and $2,444 and $2,579, respectively. These costs are included under "interest income (expense), net" in the Company’s consolidated statements of income.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||